EyePoint Pharmaceuticals Inc Phase 1 DAVIO Trial Of EYP-1901 Results Conference Call Transcript
Good day, ladies and gentlemen, and welcome to EyePoint Pharmaceuticals Data Call at American Academy of Ophthalmology. (Operator Instructions)
I would now like to turn the conference over to your first speaker today, Mr. George Elston, CFO. Sir, the floor is yours.
Thank you, and thank you all for joining us on today's conference call to discuss our positive top line safety and efficacy results from the Phase I DAVIO trial evaluating EYP-1901 for the treatment of Wet AMD.
I am George Elston, the CFO of EyePoint Pharmaceuticals, and with me today is Nancy Lurker, President and Chief Executive Officer; Dr. Jay Duker, Chief Operating Officer; Dr. Dario Paggiarino, Chief Medical Officer; and Dr. Carl Regillo, KOL and Chairman of the company's Scientific Advisory Board.
Earlier this morning, we issued a press release detailing our results. We are using slides to accompany our remarks today, which will be found in the Investor Relations tab on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
